Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Lymphoma updates: CAR-T, brentuximab & nivolumab

Nathan Fowler, MD, University of Texas MD Anderson Cancer Center, Houston, TX, highlights key lymphoma news from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. These include updates on JCAR017 in non-Hodgkin lymphoma, and the combination of bretuximab vedotin and the checkpoint inhibitor nivolumab in Hodgkin lymphoma.